Mouse anti Zika virus envelope protein Zika virus NS1 protein Zika Virus VLP Zika Virus Envelope Protein purified zika virus lysate zika virus vero cell lysate Mouse anti Zika virus NS1 antibody Mouse anti Flavivirus Envelope protein antibody (4G2) Human IgG1 Anti Zika Virus NS1 monoclonal antibody Human IgM Anti Zika Virus NS1 monoclonal antibody

Zika Virus NS1 protein (Uganda strain)

Product TypeMammalian recombinant, his-tagged
Purity>90% pure by SDS-PAGE
StrainUganda MR 766
PresentationLiquid
Protein Conc.~0.5 mg/ml
Product CodeZIKV-NS1
Vial Size100μg | 500μg

From: $457.25

Clear
SKU: ZIKV-NS1 Categories: ,

Product Description

Zika Virus NS1 protein (Uganda strain)

Zika virus NS1 protein 1 (Non-Structural protein 1) has been manufactured in response to the unmet need for highly purified, concentrated protein for use in serological based diagnostic assays. Zika virus NS1 protein is engineered in human cells using state-of-the-art expression and purification techniques.

Zika virus is an emerging disease that is spread by Aedes mosquitoes. The virus was first isolated in Central Africa, and has since been spread to South Asia and recently to South America. Outbreaks were reported in Micronesia in 2007 and in Brazil in 2015, confirming at least 13 autochthonous infections.The Zika virus outbreak in Brazil in 2016 has gained world-wide attention, and has been linked to an increasing number of microcephaly cases.  In April 2016 the Centers for Disease Control, in the USA,  confirmed the link between Zika virus infection of the fetus with microcephaly.

Zika virus can cause mild fever, rash, myalgia, arthralgia and headaches, with one in four infected individuals being asymptomatic. Due to similar symptoms Zika virus infected individuals can easily be mis-diagnosed as a dengue infection and vice-versa. In addition, Zika virus has been implicated in causing microcephaly through transmission in utero. There is no vaccine or specific treatment available for Zika virus.

Analysis of Zika virus sequences from infected patients have shown that the strain circulating in South America in 2015 differs to the strain originally isoloated in 1947 in Uganda (the “Uganda” strain). The South American strain was first isolated and sequenced from a patient in Suriname, and hence is known as the Zika Suriname strain. 7.   The Native Antigen Company are pleased to make available Zika Virus NS1 protein from both the Uganda and Suriname strains, enabling researchers to carefully study the differences between the two antigens and the host response to them.

Zika virus NS1 has been produced to the same standards as other NS1 proteins, and is presented as a highly purified liquid protein.

 

****SHIPPING NOTIFICATION: All NS1 products are shipped at ambient temperature. Extensive stability tests have shown no negative effects on antigen performance for 7 days of shipping including several freeze/thaw cycles. Should customers desire shipment on dry ice, this can be performed for an extra fee, please get in contact with us by phone or email.****

Additional Information

Vial Size

100μg, 500μg

2015-15-21 CofA ZIKV NS1-100 Batch 15120909  2015-15-21 CofA ZIKV NS1-100 Batch 15120909

SDS ZIKV NS1  SDS ZIKV NS1

Menu